FEATURES OF NEUROLOGICAL COMPLICATIONS AFTER KOVID 19 INFECTION

Article Sidebar

PDF (English)
Выпуск: Том 1 № 27 : Zamonaviy dunyoda innovatsion tadqiqotlar: Nazariya va amaliyot
Раздел: Статьи
Опубликован:

Main Article Content

ASMI Associate Professor of the Department of Neurology
info@in-academy.uz
Andijan State Medical Institute.
info@in-academy.uz
Andijan State Medical Institute.
info@in-academy.uz

Аннотация:

This article provides information about the COVID-19 disease based on statistics and research.

Article Details

Как цитировать:

Abdukadirova , D. ., Akmaljon o’g’li, S. ., & Mamasoliev, S. (2022). FEATURES OF NEUROLOGICAL COMPLICATIONS AFTER KOVID 19 INFECTION . Инновационные исследования в современном мире: теория и практика, 1(27), 20–24. извлечено от https://in-academy.uz/index.php/zdit/article/view/6026

Библиографические ссылки:

Brian Let al. Escitalopram: translating molecular properties into clinical benefit: reviewing the evidentein major depression. Journal of Psychopharmacology 2010, 24 (8) 11431152

Nasar Sayeed Khan, M. et al. Escitalopram in treatment of obsessive-compulsive disorder: a double blind placebo control trial. J Ayub Coll Abbottabad 2007, 19(4)58.

Ian R. et al. Depression: current approaches to management in primary care. Prescriber Feb 19, 2009. www.prescriber.co.uk

Robert Valuck. Selective Serotonin Reuptake inhibitors: A Class Review. Apr 2004 Vol. 29 no. 4, 234-243. 9.

Sidney H. et al. Escitalopram the treatment of major depressive disorder: Ameta-analysis. Current Medical Resarch and Opinion/Vol. 25, no. 1, 2009, 161175.

Boulenger J. P. et al. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current Medical Research and Opinion Vol. 22, No 7, 2006, 13311341.

Turner E. H. et al. Serotonin a la carte: Supplementation with the serotonib precursor 5-hydroxytryptophan/ Pharmacology and Therapeutics 05715: No of pages 14/eatment.